Purpose: To examine the utility of guanylyl cyclase C (GC-C)-specific neste
d reverse transcriptase polymerase chain reaction (RT-PCR) to detect circul
ating tumor cells in patients with colorectal cancer.
Patients and Methods: Peripheral-blood mononuclear cells from 24 patients w
ith Dukes' stage D colorectal cancer were analyzed by GC-C-specific nested
RT-PCR using 1 mug of total RNA. Peripheral-blood mononuclear cells from 20
healthy volunteers served as controls. Additionally, peripheral-blood CD34
(+) progenitor cells were assayed for the expression of both GC-C and other
epithelial cell-specific markers.
Results: GC-C mRNA was detected in blood mononuclear cells from all 24 pati
ents with colorectal cancer and all healthy volunteers. These unexpected po
sitive results reflected low-level ectopic transcription of GC-C in CD34(+)
progenitor cells. Moreover, CD34(+) progenitor cells expressed other epith
elial cell-specific markers, including prostate-specific antigen, prostate-
specific membrane antigen, carcinoembryonic antigen, CK-19, CK-20, mucin 1,
and GA733.2. Limiting the quantity of mononuclear cell total RNA analyzed
to less than or equal to 0.8 mug eliminated detection of GC-C and other tis
sue-specific transcripts in blood of healthy volunteers. However, under the
same conditions, GC-C mRNA was detected in mononuclear cells from all 24 p
atients with metastatic colorectal cancer. Using 0.5 mug of total RNA and G
C-C-specific primers, nested RT-PCR detected a single human colon carcinoma
cell (approximately 20 to 200 GC-C transcripts/cell) in 10(6) to 10(7) mon
onuclear blood cells.
Conclusion: These data suggest that GC-C may be useful for detecting circul
ating colorectal cancer cells. They also demonstrate that CD34(+) cells are
a source of ectopically expressed epithelial cell-specific markers and tha
t CD34(+) cells may contribute to the high falsepositive rate generally obs
erved when those markers are used to detect rare circulating metastatic can
cer cells by RT-PCR. (C) 2001 by American Society of Clinical Oncology.